Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Radiopharm Theranostics Limited Sponsored ADR ( (RADX) ) has shared an announcement.
On 24 February 2026 Radiopharm Theranostics announced it had dosed the first patient in a First-In-Human Phase 1/2a clinical trial of 177Lu-BetaBart (RV-01), a radiotherapeutic developed through Radiopharm Ventures, its joint venture with The University of Texas MD Anderson Cancer Center. The agent is a Lu-177–tagged monoclonal antibody targeting the 4Ig isoform of B7-H3, an immune checkpoint molecule overexpressed in several tumor types, and preclinical studies have shown tumor shrinkage and prolonged survival in animal models.
The Phase 1/2a study, which follows prior FDA IND clearance in July 2025, is designed as a dose-escalation and expansion trial to assess safety, biodistribution, pharmacokinetics, radiation dosimetry and preliminary anti-tumor activity, and to establish a recommended dose for future studies. Radiopharm plans to enroll 61 patients with various advanced refractory solid tumors, including prostate, colorectal, lung, head and neck, ovarian and triple-negative breast cancers, marking a significant milestone as the first radiotherapeutic from the joint venture to enter the clinic and potentially broadening the company’s footprint in targeted radiopharmaceutical oncology.
The most recent analyst rating on (RADX) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited Sponsored ADR stock, see the RADX Stock Forecast page.
Spark’s Take on RADX Stock
According to Spark, TipRanks’ AI Analyst, RADX is a Neutral.
The score is held down primarily by sustained losses and persistent cash burn (negative operating and free cash flow), despite some revenue momentum. Technical signals are largely neutral with only mild positives, offering limited support. Valuation is difficult to assess due to negative earnings, and no dividend data is available.
To see Spark’s full report on RADX stock, click here.
More about Radiopharm Theranostics Limited Sponsored ADR
Radiopharm Theranostics Limited is a clinical-stage radiotherapeutics company developing innovative radiopharmaceutical products for diagnostic and therapeutic use in oncology. Listed on the ASX and Nasdaq, the company’s pipeline spans peptides, small molecules and monoclonal antibodies targeting a range of solid tumors, with one Phase 2 and four Phase 1 trials underway in indications including lung, breast and brain metastases.
Average Trading Volume: 749,540
Technical Sentiment Signal: Buy
Current Market Cap: $54.81M
For an in-depth examination of RADX stock, go to TipRanks’ Overview page.